Pentamidine

Generic Name: Pentamidine

Brand Names: Nebupent, Pentam

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₄N_₄O_₂

CAS Number: 100-33-4

Unique Ingredient Identifier: 673LC5J4LQ

Background: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.

Indication: For the treatment of pneumonia due to Pneumocystis carinii.

Associated Conditions: Pneumocystis Jirovecii Pneumonia, Trypanosomiasis

Associated Therapies: -

Clinical Trials

Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

Phase 1

Completed

Conditions: Refractory Hodgkin Lymphoma
Hodgkin Lymphoma

Interventions: Drug: Pentamidine

First Posted Date: 2018-11-05

Last Posted Date: 2021-07-07

Lead Sponsor: Reinhold Munker

Target Recruit Count: 1

Registration Number: NCT03730363

Locations: 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States

Hypertrophic Scar Prevention by Novel Topical Gel Application

Phase 1

Terminated

Conditions: Hypertrophic Scar

Interventions: Drug: Pentamidine Isethionate
Drug: Placebo

First Posted Date: 2018-01-18

Last Posted Date: 2023-11-22

Lead Sponsor: Mayo Clinic

Target Recruit Count: 6

Registration Number: NCT03403621

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia

Phase 2

Completed

Conditions: Leishmaniasis, Cutaneous
Leishmania Braziliensis Complex
Leishmaniasis, American
Leishmaniasis; American, Cutaneous

Interventions: Drug: Paromomycin Sulfate
Other: Placebo
Drug: Pentamidine Isethionate

First Posted Date: 2017-03-30

Last Posted Date: 2021-02-02

Lead Sponsor: Fundacion Nacional de Dermatologia

Target Recruit Count: 80

Registration Number: NCT03096457

Locations: 🇧🇴
Hospital Dermatologico de Jorochito, Jorochito, SC, Bolivia
🇧🇴
Hospital Local Palos Blancos, Palos Blancos, La Paz, Bolivia

Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia

Completed

Conditions: Hematologic Malignancy

Interventions: Drug: Pentamidine

First Posted Date: 2016-02-01

Last Posted Date: 2016-06-30

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 50

Registration Number: NCT02669706

Locations: 🇺🇸
University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States

Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study

Phase 3

Completed

Conditions: HIV-infection/Aids
Visceral Leishmaniosis

Interventions: Drug: Pentamidine

First Posted Date: 2011-05-26

Last Posted Date: 2019-02-15

Lead Sponsor: Institute of Tropical Medicine, Belgium

Target Recruit Count: 74

Registration Number: NCT01360762

Locations: 🇪🇹
Abdurafi Health Center/Médecins Sans Frontières, Abdurafi, Amhara, Ethiopia
🇪🇹
Kahsay Abera Hospital, Humera, Tigray, Ethiopia
🇪🇹
Leismania Research and Treatment Centre, University of Gondar Hospital, Gondar, Ethiopia

A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Pentamidine

First Posted Date: 2008-12-18

Last Posted Date: 2011-06-28

Lead Sponsor: Oncozyme Pharma Inc.

Target Recruit Count: 10

Registration Number: NCT00810953

Locations: 🇨🇦
McGill University, Montreal, Quebec, Canada

A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: pentamidine

First Posted Date: 2008-12-17

Last Posted Date: 2011-06-28

Lead Sponsor: Oncozyme Pharma Inc.

Target Recruit Count: 15

Registration Number: NCT00809796

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

Phase 2

Completed

Conditions: African Trypanosomiasis

Interventions: Drug: DB289
Drug: Pentamidine

First Posted Date: 2008-12-08

Last Posted Date: 2008-12-08

Lead Sponsor: Immtech Pharmaceuticals, Inc

Target Recruit Count: 111

Registration Number: NCT00803933

Locations: 🇨🇬
CDTC Maluku, Gombe, Kinshasa, Congo
🇨🇬
Vanga Hospital, Gombe, Kinshasa, Congo

0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma

Phase 2

Terminated

Conditions: Melanoma (Skin)

Interventions: Drug: pentamidine

First Posted Date: 2008-08-08

Last Posted Date: 2019-08-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 6

Registration Number: NCT00729807

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: Bleomycin Sulfate
Biological: Filgrastim
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride (DOX)
Drug: Fluorouracil
Drug: Leucovorin calcium
Drug: Etoposide
Drug: Pentamidine
Drug: Prednisone
Drug: Ifosfamide
Drug: Trimethoprim-Sulfamethoxazole
Drug: Methotrexate
Drug: Vincristine Sulfate
Drug: Methylprednisolone
Drug: Zidovudine (AZT)
Radiation: Radiation Therapy

First Posted Date: 2004-10-05

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00002524

Locations: 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy